Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRTS
CUSIPN/A
Phone561-922-5808
Debt
Debt-to-Equity Ratio0.38
Current Ratio3.90
Quick Ratio3.65
Price-To-Earnings
Trailing P/E Ratio-26.54
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$20.59 million
Price / Sales4.90
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book8.54
Profitability
EPS (Most Recent Fiscal Year)($0.28)
Net Income$-3,710,000.00
Net Margins-14.71%
Return on Equity-27.39%
Return on Assets-17.14%
Miscellaneous
Employees45
Outstanding Shares13,570,000
Sensus Healthcare (NASDAQ:SRTS) Frequently Asked Questions
What is Sensus Healthcare's stock symbol?
Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."
How were Sensus Healthcare's earnings last quarter?
Sensus Healthcare Inc (NASDAQ:SRTS) released its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.01. The firm earned $5.96 million during the quarter, compared to the consensus estimate of $5.28 million. Sensus Healthcare had a negative return on equity of 27.39% and a negative net margin of 14.71%. View Sensus Healthcare's Earnings History.
What price target have analysts set for SRTS?
1 brokers have issued twelve-month price objectives for Sensus Healthcare's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Sensus Healthcare's share price to reach $9.00 in the next twelve months. View Analyst Ratings for Sensus Healthcare.
Who are some of Sensus Healthcare's key competitors?
Some companies that are related to Sensus Healthcare include GenMark Diagnostics (GNMK), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Accuray (ARAY), Westaim (WEDXF), Orthopediatrics (KIDS), Cytosorbents (CTSO), Nuvectra (NVTR), Pulse Biosciences (PLSE), RenovaCare (RCAR), SeaSpine (SPNE), Iradimed (IRMD), Apollo Endosurgery (APEN), Motus GI (MOTS) and Invuity (IVTY).
Who are Sensus Healthcare's key executives?
Sensus Healthcare's management team includes the folowing people:
- Mr. Joseph C. Sardano, Chairman, CEO & Pres (Age 65)
- Mr. Arthur R. Levine, CFO & Principal Accounting Officer
- Mr. Stephen Cohen, Exec. VP of Dermatology Sales & Marketing (Age 58)
- Mr. Kalman Fishman, Chief Operating Officer and Chief Technology Officer (Age 47)
- Michael Sardano, Gen. Counsel and Corp. Sec.
When did Sensus Healthcare IPO?
(SRTS) raised $20 million in an initial public offering (IPO) on Wednesday, March 30th 2016. The company issued 1,800,000 shares at $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company acted as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.
Has Sensus Healthcare been receiving favorable news coverage?
Media headlines about SRTS stock have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sensus Healthcare earned a news impact score of 0.24 on Accern's scale. They also assigned news articles about the company an impact score of 47.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Sensus Healthcare's major shareholders?
Sensus Healthcare's stock is owned by many different of retail and institutional investors. Top institutional investors include Commonwealth Equity Services LLC (0.18%). Company insiders that own Sensus Healthcare stock include Arthur Levine, Joseph C Sardano, Kalman Fishman, Richard Golin and Stephen Brad Cohen. View Institutional Ownership Trends for Sensus Healthcare.
Which institutional investors are buying Sensus Healthcare stock?
How do I buy shares of Sensus Healthcare?
Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sensus Healthcare's stock price today?
One share of SRTS stock can currently be purchased for approximately $7.43.
How big of a company is Sensus Healthcare?
Sensus Healthcare has a market capitalization of $100.95 million and generates $20.59 million in revenue each year. The company earns $-3,710,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Sensus Healthcare employs 45 workers across the globe.
How can I contact Sensus Healthcare?
Sensus Healthcare's mailing address is 851 BROKEN SOUND PKWY. NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at 561-922-5808 or via email at [email protected]
MarketBeat Community Rating for Sensus Healthcare (SRTS)
MarketBeat's community ratings are surveys of what our community members think about Sensus Healthcare and other stocks. Vote "Outperform" if you believe SRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
